TABLE 2.
N | Median overall survival (mo) |
HRa | (95 % CI) | p value | |
---|---|---|---|---|---|
Total | 88 | 18.4 (15.3–21.3) | |||
OS from date of diagnosis | |||||
Protocol patients | 40 | 18.83 (14.8–23.8) | 1.00 | – | |
Nonprotocol patients | 48 | 17.08 (14.6–27.2) | 1.13 | (0.66–1.96) | 0.65 |
Tumor in body or tail | 19 | NA | 1.00 | – | |
Tumor in head, neck, or uncinate | 69 | 17.08 (14.6–21.2) | 2.00 | (0.76–4.9) | 0.17 |
Baseline ECOG 0 | 38 | 18.86 (16.7–27.2) | 1.00 | – | |
Baseline ECOG ≥ 1 | 50 | 15.34 (11.3–22.2) | 1.47 | (0.85–2.53) | 0.16 |
No baseline pain | 47 | 19.52 (16.1–27.9) | 1.00 | – | |
Baseline pain | 41 | 15.34 (14.4–21.2) | 1.58 | (0.87–2.62) | 0.14 |
Baseline CA19-9 < 168 U/µL | 41 | 19.12 (17.1–45.2) | 1.00 | – | |
Baseline CA19-9 ≥ 168 U/µL | 42 | 16.07 (11.0–21.3) | 1.59 | (0.91–2.77) | 0.1 |
Pre-SBRT chemotherapy | 77 | 18.83 (16.1–22.2) | 0.54 | (0.23–1.09) | 0.1 |
No pre-SBRT chemotherapy | 11 | 9.00 (8.0–45.2) | 1.00 | ||
Borderline resectable | 14 | 14.39 (11.0–45.2) | 0.88 | (0.31–2.49) | 0.81 |
Locally advanced | 74 | 18.41 (15.3–21.3) | 1.00 | – | |
Pre-SBRT stent placed | 28 | 17.87 (11.3–45.2) | 1.05 | (0.58–1.89) | 0.88 |
Pre-SBRT no stent placed | 60 | 18.83 (14.8–22.2) | 1.00 | – | |
OS from start of SBRT | |||||
Protocol patients | 40 | 18.2 (11.7–22.3) | 1.00 | – | |
Nonprotocol patients | 48 | 12.7 (9.4–18.2) | 1.61 | (0.92–2.82) | 0.09 |
No surgical resection | 69 | 12.75 (9.7–18.2) | 1.00 | ||
Surgical resection | 19 | 20.24 (12.5–42.4) | 0.34 | (0.10–1.08) | 0.07 |
Post SBRT ECOG 0 | 44 | 18.27 (14.6–42.4) | 1.00 | – | |
Post SBRT ECOG ≥ 1 | 44 | 11.73 (7.8–18.2) | 1.56 | (0.89–2.71) | 0.12 |
Post SBRT CA19-9 < 62 U/µL | 36 | 15.01 (12.8–24.3) | 1.00 | – | |
Post SBRT CA19-9 ≥ 62 U/µL | 39 | 12.42 (9.2–19.9) | 1.34 | (0.75–2.37) | 0.32 |
Fraction size 6.6 Gy/fx | 54 | 13.7 (9.7–19.9) | 1.00 | – | |
Fraction size < 6.6 Gy/fx | 34 | 13.0 (12.4–42.4) | 1.12 | (0.63–1.99) | 0.69 |
Statistically significant (p < 0.05)
Hazard ratios from diagnosis are adjusted for age, sex, race and a time-dependent covariate for the time between diagnosis and treatment. Hazard ratios from treatment are adjusted for age, sex, and race only